ISA Pharmaceuticals’ ISA101 Studied in Phase II Combination Trial with Checkpoint Inhibitor Nivolumab

07 Dec 2015

– Trial in patients with HPV16-positive, incurable solid tumors initiated by MD Anderson Cancer Center in collaboration with ISA and Bristol-Myers Squibb

Leiden, The Netherlands, December 7, 2015 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, today announced the start of a Phase II combination trial, which will be conducted at The University of Texas MD Anderson Cancer Center (Houston, TX).

The goal of the open-label Phase II study is to investigate whether a combination of ISA101 with Nivolumab can help to control cancer that has spread in the body. The

Read more »